High Grade Meningioma
Conditions
Brief summary
This is a randomized, controlled, open-label, multicenter, Phase III clinical study designed to compare the efficacy and safety of SYHA1813 versus treatment of investigators' choice in patients with recurrent or progressive high-grade meningioma not amenable to local therapy.
Detailed description
Approximately136 participants with recurrent or progressive high-grade meningioma who have received surgical resection and radiotherapy will be enrolled and randomized 1:1 to receive either SYHA1813 (experimental group) or investigators' choice (control group) treatment. The primary endpoint is progression-free survival (PFS) assessed by blinded Independent Review Committee (BIRC) using the Response Assessment in Neuro-Oncology Working Group (RANO criteria) for meningioma.
Interventions
DRUGSYHA1813
SYHA1813 20mg QD
Investigator's Choice Treatment：bevacizumab, temozolomide or hydroxyurea
Sponsors
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is a randomized, controlled, open-label, multicenter, Phase III clinical trial. Participants with recurrent or progressive high-grade meningioma (WHO Grade II and III) who have received surgical resection and radiotherapy and are not eligible for local therapy judged by investigator will be randomized 1:1 to receive either SYHA1813 (experimental group) or investigators' choice (control group) treatment.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1\. Aged \>= 18 years. * 2\. Histologically confirmed WHO grade II/III meningioma (WHO CNS 5th) that is progressive or recurrent. * 3\. Individuals must have received surgery and radiation therapy. * 4\. There is at least one measurable intracranial tumor lesion in the baseline period (RANO-meningioma). * 5\. KPS≥60. * 6\. The expected survival time is \>=3 months. * 7\. The organ function level and related laboratory indicators must meet requirement. * 8\. Agree to use reliable and effective methods of contraception during the study treatment period and for at least 3 months after the last study treatment.
Exclusion criteria
* 1\. Individuals who are known to have severe allergic reaction to the study drug or any other ingredients/excipients in the formulation. * 2\. Meets one of the following conditions: patients with brainstem involvement or extracranial metastasis; patients with severe brain herniation or at risk of brain herniation. * 3\. History of other malignant tumors within 3 years or concurrent active malignant tumors. * 4\. The toxic reactions of previous anti-tumor treatments have not yet recovered to ≤ Grade 1. * 5\. Have used potent inhibitors or inducers of CYP3A4, CYP2C19 or CYP1A2 within the 14 days prior to randomization or are still requiring continued use of such agents. * 6\. Individuals currently receiving warfarin or other oral anticoagulants (excluding those who use low-dose anticoagulants to maintain patency of central venous access or prevent deep vein thrombosis). * 7\. Individuals who are unable to undergo enhanced MRI (such as those with pacemakers, metal dentures, claustrophobia, contrast agent allergies, etc.). * 8\. Individuals with evidence or medical history of bleeding tendency within 2 months prior to randomization. * 9\. Individuals with urine protein ≥ 2+, and 24-hour quantitative urine protein ≥ 1.0 g/24 h upon testing. * 10\. History of acquired immunodeficiency syndrome or HIV antibody positivity in the past; Active hepatitis C; Active hepatitis B. * 11\. Individuals with poorly healing wounds or ulcers, or fractures that require treatment or exhibit poor healing. * 12\. Within 14 days prior to randomization, there were severe chronic or active infections (including tuberculosis infections) that required intravenous injection of antibacterial, antifungal or antiviral therapy. * 13\. Individuals with cardiovascular and cerebrovascular diseases of significant clinical significance. * 14\. Have undergone surgery of major vital organs within 28 days prior to randomization (excluding puncture biopsy). * 15\. Individuals with swallowing difficulties or known medication absorption disorders. * 16\. Pregnant or lactating women. * 17\. Any other conditions that may interfere with the participant's adherence to study procedures, compromise the participant's best interests in participating in the study, or affect study results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival (PFS) as Assessed by RANO Criteria and Evaluated by BIRC | Up to approximately 4 years |
Secondary
| Measure | Time frame |
|---|---|
| PFS as Assessed by RANO Criteria and Evaluated by investigators | Up to approximately 4 years |
| Overall Survival (OS) | Up to approximately 4 years |
| Overall Survival Rate at 12 Months (OS-12) | Up to approximately 4 years |
| Progression Free Survival Rate at 6 Months (PFS-6) as Assessed by RANO Criteria | Up to approximately 4 years |
| Objective Response Rate (ORR) as Assessed by RANO Criteria | Up to approximately 4 years |
| Disease Control Rate (DCR) as Assessed by RANO Criteria | Up to approximately 4 years |
| Frequency and severity of TEAEs and SAEs | Up to approximately 4 years |
| Cmax of SYHA1813 | Cycles 1, 2, 3 |
| Tmax of SYHA1813 | Cycles 1, 2, 3 |
| AUClast of SYHA1813 | Cycles 1, 2, 3 |
| AUCinf of SYHA1813 | Cycles 1, 2, 3 |
| t1/2 of SYHA1813 | Cycles 1, 2, 3 |
Contacts
CONTACTClinical Trials Information Group officer
Outcome results
None listed